Published in Prostate on May 01, 2004
Epigenetics in cancer. Carcinogenesis (2009) 7.49
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer (2008) 2.67
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer (2013) 2.41
Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol (2007) 2.07
Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis (2005) 2.05
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res (2010) 2.01
Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (Maywood) (2007) 1.98
Multi-targeted prevention of cancer by sulforaphane. Cancer Lett (2008) 1.98
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem (2012) 1.74
Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci (2010) 1.61
Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci U S A (2009) 1.46
Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther (2010) 1.45
Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays. PLoS One (2015) 1.40
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics (2013) 1.38
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis (2013) 1.37
HDAC1 promotes liver proliferation in young mice via interactions with C/EBPbeta. J Biol Chem (2008) 1.29
Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention. J Nutr (2009) 1.27
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer (2008) 1.26
Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2. J Biomed Biotechnol (2010) 1.26
Histone deacetylase 2 is required for chromatin condensation and subsequent enucleation of cultured mouse fetal erythroblasts. Haematologica (2010) 1.25
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res (2009) 1.23
The role of histone deacetylases in prostate cancer. Epigenetics (2008) 1.21
Chromatin, cancer and drug therapies. Mutat Res (2008) 1.21
Epigenetic alterations in aging. J Appl Physiol (1985) (2010) 1.20
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat (2011) 1.18
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology (2008) 1.18
Intracellular signaling and hepatocellular carcinoma. Semin Cancer Biol (2010) 1.17
Histone modifications and cancer: biomarkers of prognosis? Am J Cancer Res (2012) 1.15
Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol Cell Biol (2006) 1.12
Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis (2011) 1.12
Histone deacetylase inhibitors globally enhance h3/h4 tail acetylation without affecting h3 lysine 56 acetylation. Sci Rep (2012) 1.11
Interactions between epigenetics and metabolism in cancers. Front Oncol (2012) 1.11
Histone deacetylase inhibitors through click chemistry. J Med Chem (2008) 1.10
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene (2012) 1.08
The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene (2012) 1.07
Increased expression of enzymes of triglyceride synthesis is essential for the development of hepatic steatosis. Cell Rep (2013) 1.06
Vitamin D and the epigenome. Front Physiol (2014) 1.04
Largazole: from discovery to broad-spectrum therapy. Nat Prod Rep (2012) 1.03
Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans. EMBO J (2010) 1.03
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. Pharmaceuticals (Basel) (2010) 1.02
Histone deacetylase inhibitors and cell death. Cell Mol Life Sci (2014) 1.00
Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin Exp Metastasis (2011) 1.00
Histone deacetylases as targets for the treatment of human neurodegenerative diseases. Drug News Perspect (2009) 1.00
Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol (2011) 1.00
Dietary factors and epigenetic regulation for prostate cancer prevention. Adv Nutr (2011) 1.00
Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res (2009) 0.99
Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int J Cancer (2009) 0.99
R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer (2007) 0.98
Macrocyclic histone deacetylase inhibitors. Curr Top Med Chem (2010) 0.98
Regulators of gene expression as biomarkers for prostate cancer. Am J Cancer Res (2012) 0.98
Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS One (2012) 0.97
3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. Toxicol Appl Pharmacol (2012) 0.96
Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: in vitro and in vivo study. Mol Carcinog (2011) 0.95
Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes Cancer (2015) 0.95
Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. Epigenetics (2012) 0.94
Epigenetics in non-small cell lung cancer: from basics to therapeutics. Transl Lung Cancer Res (2016) 0.94
Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors. Curr Top Med Chem (2009) 0.93
HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Med J (2016) 0.93
Epigenetic regulation of androgen receptor signaling in prostate cancer. Epigenetics (2010) 0.92
Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer. PLoS One (2013) 0.92
HDACs and the senescent phenotype of WI-38 cells. BMC Cell Biol (2005) 0.90
HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells. Mol Cancer Res (2011) 0.90
Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis. Am J Respir Cell Mol Biol (2012) 0.89
The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. J Hematol Oncol (2015) 0.89
The epigenetics of renal cell tumors: from biology to biomarkers. Front Genet (2012) 0.89
Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. J Thorac Oncol (2010) 0.88
Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas. Korean J Pathol (2012) 0.87
Discovery and mechanism of natural products as modulators of histone acetylation. Curr Drug Targets (2012) 0.87
Histone Deacetylase Inhibitors Activate Tristetraprolin Expression through Induction of Early Growth Response Protein 1 (EGR1) in Colorectal Cancer Cells. Biomolecules (2015) 0.86
Genomic and Epigenomic Alterations in Cancer. Am J Pathol (2016) 0.86
Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer. Cancer Biol Ther (2011) 0.86
Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem (2013) 0.86
Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells. PLoS One (2013) 0.85
The role of dietary histone deacetylases (HDACs) inhibitors in health and disease. Nutrients (2014) 0.85
Epigenetic mechanisms in commonly occurring cancers. DNA Cell Biol (2012) 0.84
A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells. Invest New Drugs (2011) 0.84
New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma. J Cell Mol Med (2008) 0.84
Common stemness regulators of embryonic and cancer stem cells. World J Stem Cells (2015) 0.84
Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clin Pathol (2014) 0.84
Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi). PLoS One (2013) 0.83
Epigenetic linkage of aging, cancer and nutrition. J Exp Biol (2015) 0.83
Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer. Am J Cancer Res (2015) 0.82
Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells. BMC Complement Altern Med (2014) 0.81
Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70-Bax interaction in prostate cancer. Apoptosis (2014) 0.80
Synthesis and activity of tumor-homing peptide iRGD and histone deacetylase inhibitor valproic acid conjugate. Bioorg Med Chem Lett (2014) 0.80
Polyphenols from green tea inhibit the growth of melanoma cells through inhibition of class I histone deacetylases and induction of DNA damage. Genes Cancer (2015) 0.79
An integrative proteomics and interaction network-based classifier for prostate cancer diagnosis. PLoS One (2013) 0.79
Epigenetic regulation of prostate cancer. Clin Epigenetics (2011) 0.79
SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. Cancer Biol Ther (2014) 0.79
New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Prostate Cancer (2011) 0.79
In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma. Pediatr Surg Int (2012) 0.79
Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects. Onco Targets Ther (2012) 0.79
Genetic and epigenetic changes in human prostate cancer. Iran Red Crescent Med J (2011) 0.79
Largazole pharmacokinetics in rats by LC-MS/MS. Mar Drugs (2014) 0.78
Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators. FASEB J (2014) 0.78
Expression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: a tissue microarray study. BMC Cancer (2011) 0.77
A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J (2011) 0.77
A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1. Biomol Ther (Seoul) (2015) 0.77
MicroRNAs as New Characters in the Plot between Epigenetics and Prostate Cancer. Front Genet (2011) 0.77
Histones: Controlling Tumor Signaling Circuitry. J Carcinog Mutagen (2013) 0.77
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst (2008) 5.82
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci (2004) 4.76
Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ (2012) 4.64
Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet (2009) 3.94
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med (2010) 2.83
Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. Control Clin Trials (2003) 2.70
The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell (2012) 2.59
Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet (2011) 2.51
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet (2011) 2.43
Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer (2011) 2.42
Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. J Clin Epidemiol (2008) 2.40
A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nat Genet (2012) 2.29
Cellular functions of TIP60. Int J Biochem Cell Biol (2006) 2.28
The role of surgery in high-risk localised prostate cancer. BJU Int (2011) 2.19
New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep (2007) 2.17
First 500 cases of robotic-assisted laparoscopic radical prostatectomy from a single UK centre: learning curves of two surgeons. BJU Int (2010) 2.12
Prostate specific antigen enhances the innate defence of prostatic epithelium against Escherichia coli infection. Prostate (2013) 2.03
Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J Biol Chem (2002) 1.95
Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. Biochem J (2010) 1.93
Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res (2005) 1.83
Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer (2011) 1.81
Psychological impact of prostate biopsy: physical symptoms, anxiety, and depression. J Clin Oncol (2013) 1.78
Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet (2013) 1.78
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J (2011) 1.72
Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. Cancer Res (2011) 1.71
Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study). J Clin Epidemiol (2003) 1.71
Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer (2010) 1.64
Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial. Eur Urol (2007) 1.64
The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res (2008) 1.58
Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene (2003) 1.56
Key considerations for the experimental training and evaluation of cancer odour detection dogs: lessons learnt from a double-blind, controlled trial of prostate cancer detection. BMC Urol (2014) 1.55
Structural basis for the nuclear import of the human androgen receptor. J Cell Sci (2008) 1.53
Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res (2006) 1.52
A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. Hum Mol Genet (2013) 1.52
A novel model of urinary tract differentiation, tissue regeneration, and disease: reprogramming human prostate and bladder cells into induced pluripotent stem cells. Eur Urol (2013) 1.51
Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells? BJU Int (2012) 1.51
Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. Cochrane Database Syst Rev (2012) 1.50
Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. Eur Urol (2009) 1.49
It's not just what you say, it's also how you say it: opening the 'black box' of informed consent appointments in randomised controlled trials. Soc Sci Med (2009) 1.48
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet (2012) 1.47
SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res (2009) 1.47
Oral ciprofloxacin or trimethoprim reduces bacteriuria after flexible cystoscopy. BJU Int (2007) 1.46
LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals. Clin Cancer Res (2009) 1.41
Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev (2010) 1.40
Exploring treatment preferences facilitated recruitment to randomized controlled trials. J Clin Epidemiol (2011) 1.40
RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia (2012) 1.36
Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A (2012) 1.34
Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol (2009) 1.33
Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene (2005) 1.33
Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). Int J Cancer (2011) 1.30
Identification of a novel, selective GABA(A) alpha5 receptor inverse agonist which enhances cognition. J Med Chem (2003) 1.29
Regulation of the androgen receptor by post-translational modifications. J Endocrinol (2012) 1.27
Pathways of proliferation and antiapoptosis driven in breast cancer stem cells by stem cell protein piwil2. Cancer Res (2010) 1.26
Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clin Cancer Res (2011) 1.26
Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. BJU Int (2011) 1.25
Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. BJU Int (2006) 1.24
Sprouty and cancer: the first terms report. Cancer Lett (2006) 1.22
Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. BJU Int (2009) 1.21
Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev (2009) 1.18
A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. BMC Genomics (2007) 1.17
Regulation of the androgen receptor by SET9-mediated methylation. Nucleic Acids Res (2010) 1.17
Alterations in beta-catenin expression and localization in prostate cancer. Prostate (2008) 1.16
A human T-cell lymphotropic virus type 1 enhancer of Myc transforming potential stabilizes Myc-TIP60 transcriptional interactions. Mol Cell Biol (2005) 1.15
Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. Neoplasia (2011) 1.15
Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor. Cancer Res (2004) 1.15
Control of human PIRH2 protein stability: involvement of TIP60 and the proteosome. J Biol Chem (2003) 1.14
Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Mol Cell Biol (2006) 1.12
In situ lineage tracking of human prostatic epithelial stem cell fate reveals a common clonal origin for basal and luminal cells. J Pathol (2011) 1.12
The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene. Int J Cancer (2011) 1.09
Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta (2012) 1.09
K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Dis Model Mech (2011) 1.08
Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. Prostate (2008) 1.08
Evaluating genetic risk for prostate cancer among Japanese and Latinos. Cancer Epidemiol Biomarkers Prev (2012) 1.08
Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia (2011) 1.08
Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors. J Cell Biol (2005) 1.07